Cargando…

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes

Type 2 diabetes (T2D) is a progressive disorder with a consistent and steady increase in glycosylated hemoglobin (HbA(1)c) over time associated with enhanced risk of micro- and macrovascular complications and a substantial reduction in life expectancy. There are three major pathophysiologic abnormal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dorkhan, Mozhgan, Frid, Anders
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2007
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291316/ https://www.ncbi.nlm.nih.gov/pubmed/18078023

Ejemplares similares

Treatment with pioglitazone induced significant, reversible mitral regurgitation
por: Dorkhan, Mozhgan, et al.
Publicado: (2008)

Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes
por: Dorkhan, Mozhgan, et al.
Publicado: (2009)

Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats
por: Rao, Ravi Prakash, et al.
Publicado: (2011)

Randomized controlled trial of single‐agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: A comparative study
por: Shihara, Nobuyuki, et al.
Publicado: (2011)

Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
por: Desouza, Cyrus V., et al.
Publicado: (2010)

Aspirin potentiates blood glucose lowering effect of glimepiride-pioglitazone combination in streptozotocin-induced diabetic rats
por: Bag, Soumita, et al.
Publicado: (2014)

Risk management in the treatment of type 2 diabetes with pioglitazone
por: Derosa, Giuseppe, et al.
Publicado: (2009)

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009)

Anti-diabetic combination therapy with pioglitazone or glimepiride added to metformin on the AGE-RAGE axis: a randomized prospective study
por: Ragazzi, Eugenio, et al.
Publicado: (2023)

Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes
por: Dencker, Magnus, et al.
Publicado: (2010)

Deduction of the operable design space of RP-HPLC technique for the simultaneous estimation of metformin, pioglitazone, and glimepiride
por: Marie, Aya A., et al.
Publicado: (2023)

Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes
por: Yamanouchi, Toshikazu
Publicado: (2010)

Development and validation of the liquid chromatographic method for simultaneous estimation of metformin, pioglitazone, and glimepiride in pharmaceutical dosage forms
por: Pandit, Vinay, et al.
Publicado: (2012)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Schwartz, Stanley S
Publicado: (2010)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
por: Jeon, Hyun Jeong, et al.
Publicado: (2011)

Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib
por: Paillassa, Jérôme, et al.
Publicado: (2022)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study
por: Erdmann, Erland, et al.
Publicado: (2007)

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
por: Kim, Hae Jin, et al.
Publicado: (2022)

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
por: Hanefeld, M
Publicado: (2007)

Development and Validation of Stability-Indicating RP-HPLC Method for Simultaneous Determination of Metformin HCl and Glimepiride in Fixed-Dose Combination
por: Vaingankar, Pradnya N., et al.
Publicado: (2016)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
por: Jendle, J., et al.
Publicado: (2021)

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
por: Ahrén, Bo, et al.
Publicado: (2014)

Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride
por: Chirila, Costel, et al.
Publicado: (2015)

A Validated Adsorptive Stripping Voltammetric Determination of Antidiabetic Agent Pioglitazone HCl in Tablets and Biological Fluids
por: Al-Arfaj, Nawal Ahmad, et al.
Publicado: (2008)

Education, immigration and income as risk factors for hemoglobin A1c >70 mmol/mol when diagnosed with type 2 diabetes or latent autoimmune diabetes in adult: a population-based cohort study
por: Martinell, Mats, et al.
Publicado: (2017)

Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk
por: Zou, Cong, et al.
Publicado: (2013)

Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study
por: Kim, Jeong Mi, et al.
Publicado: (2020)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
por: Kousoulakou, Hara, et al.
Publicado: (2017)

Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients
por: Kumar, Surendra
Publicado: (2021)

Effects of pioglitazone treatment on blood leptin levels in patients with type 2 diabetes
por: Ida, Satoshi, et al.
Publicado: (2017)

Nanostructured Lipid Carrier-Based Delivery of Pioglitazone for Treatment of Type 2 Diabetes
por: Ilyas, Umair, et al.
Publicado: (2022)

Glimepiride: evidence-based facts, trends, and observations
por: Basit, Abdul, et al.
Publicado: (2012)

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
por: Sullivan, Sean D, et al.
Publicado: (2009)

Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
por: Gudipaty, Lalitha, et al.
Publicado: (2014)

Efficacy of Combination Therapy With Sitagliptin and Low-Dose Glimepiride in Japanese Patients With Type 2 Diabetes
por: Ishii, Hiroaki, et al.
Publicado: (2014)

Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients
por: Hussain, Mazhar, et al.
Publicado: (2019)

Pioglitazone and thyroid cancer risk in patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_d8gg9fisjrvjvahgnv9d2c9bi9